NEUROCRINE BIOSCIENCES INC (NBIX) Quick Ratio
- Quick ratio · latest quarter: Value 1.46×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 1.46× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $1.28B ÷ $874.50M ≈ 1.46× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 1.28B USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 874.50M USD | Liabilities, Current |
| Cash and equivalents | 332.40M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 57.40M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | 887.00M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 104.20M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.28B | $874.50M | $332.40M | $57.40M | $887.00M | $104.20M | 1.46× |
| 2026-03-31 | $2.08B | $831.70M | $266.50M | $1.05B | $768.10M | $64.50M | 2.51× |
| 2025-12-31 | $2.17B | $743.40M | $713.00M | $767.40M | $686.80M | $69.00M | 2.92× |
| 2025-09-30 | $1.84B | $638.00M | $340.20M | $774.60M | $728.00M | $69.30M | 2.89× |
| 2025-06-30 | $1.57B | $546.30M | $264.00M | $711.60M | $595.70M | $56.90M | 2.88× |
| 2025-03-31 | $1.46B | $522.90M | $194.10M | $749.40M | $516.00M | $59.10M | 2.79× |
| 2024-12-31 | $1.56B | $507.70M | $233.00M | $843.10M | $479.10M | $57.40M | 3.06× |
| 2024-09-30 | $1.71B | $429.70M | $349.10M | $878.90M | $481.10M | $45.80M | 3.98× |
| 2024-06-30 | $1.51B | $398.50M | $139.70M | $899.20M | $468.20M | $42.50M | 3.78× |
| 2024-03-31 | $1.66B | $712.90M | $396.30M | $814.30M | $450.70M | $37.20M | 2.33× |
| 2023-12-31 | (m) | $654.80M | $251.10M | $780.50M | (m) | $38.30M | (m) |
| 2023-09-30 | $1.51B | $691.60M | $293.70M | $801.40M | $417.80M | $28.80M | 2.19× |
| 2023-06-30 | $1.36B | $582.50M | $160.20M | $816.50M | $387.60M | $31.70M | 2.34× |
| 2023-03-31 | $1.29B | $374.10M | $103.80M | $790.80M | $391.60M | $33.40M | 3.44× |
| 2022-12-31 | $1.34B | $537.70M | $262.90M | $726.40M | $350.00M | $35.10M | 2.49× |
| 2022-09-30 | $1.10B | $485.10M | $212.20M | $587.20M | $301.20M | $37.00M | 2.27× |
| 2022-06-30 | $927.30M | $285.70M | $163.30M | $485.00M | $279.00M | $29.30M | 3.25× |
| 2022-03-31 | $928.40M | $253.50M | $270.20M | $394.70M | $263.50M | $29.00M | 3.66× |
| 2021-12-31 | $896.80M | $245.80M | $340.80M | $370.50M | $185.50M | $30.50M | 3.65× |
| 2021-09-30 | $929.70M | $225.90M | $311.10M | $454.80M | $163.80M | $25.50M | 4.12× |
| 2021-06-30 | $1.04B | $212.90M | $368.00M | $516.90M | $158.50M | $28.30M | 4.90× |
| 2021-03-31 | $1.02B | $190.00M | $352.60M | $521.10M | $147.80M | $30.10M | 5.38× |
| 2020-12-31 | $958.10M | $186.50M | $187.10M | $613.90M | $157.10M | $28.00M | 5.14× |
| 2020-09-30 | $1.10B | $611.00M | $425.30M | $519.40M | $156.90M | $20.60M | 1.80× |
| 2020-06-30 | $1.10B | $573.00M | $415.10M | $533.20M | $148.40M | $22.00M | 1.91× |
| 2020-03-31 | $920.30M | $140.30M | $187.00M | $584.70M | $148.60M | $21.20M | 6.56× |
| 2019-12-31 | $797.10M | $565.29M | $112.28M | $558.25M | $126.58M | $17.29M | 1.41× |
| 2019-09-30 | $785.48M | $115.65M | $166.64M | $503.52M | $115.32M | $10.80M | 6.79× |
| 2019-06-30 | $715.34M | $100.59M | $140.99M | $478.99M | $95.36M | $12.02M | 7.11× |
| 2019-03-31 | $596.03M | $72.00M | $72.78M | $451.29M | $71.96M | $13.01M | 8.28× |
| 2018-12-31 | $707.15M | $88.23M | $141.71M | $509.20M | $56.24M | $10.86M | 8.01× |
| 2018-09-30 | $689.44M | $456.40M | $195.73M | $439.61M | $54.10M | $6.05M | 1.51× |
| 2018-06-30 | $551.39M | $61.76M | $166.42M | $342.32M | $42.65M | (m) | 8.93× |
| 2018-03-31 | $505.10M | $46.47M | $175.31M | $285.17M | $44.62M | (m) | 10.87× |
| 2017-12-31 | $547.06M | $54.43M | $254.71M | $261.22M | $31.13M | (m) | 10.05× |
| 2017-09-30 | $540.84M | $38.14M | $267.82M | $243.20M | $29.82M | $242.00K | 14.18× |
| 2017-06-30 | $531.09M | $27.72M | $309.50M | $215.52M | $6.07M | $128.00K | 19.16× |
| 2017-03-31 | (m) | $23.56M | $64.09M | $171.49M | (m) | (m) | (m) |
| 2016-12-31 | (m) | $30.41M | $83.27M | $224.08M | (m) | (m) | (m) |
| 2016-09-30 | (m) | $26.67M | $99.76M | $253.28M | (m) | (m) | (m) |
| 2016-06-30 | (m) | $26.90M | $86.25M | $301.15M | (m) | (m) | (m) |
| 2016-03-31 | (m) | $23.28M | $115.30M | $266.22M | (m) | (m) | (m) |
| 2015-12-31 | (m) | $25.71M | $74.19M | $305.00M | (m) | (m) | (m) |
| 2015-09-30 | (m) | $19.82M | $66.38M | $310.47M | (m) | (m) | (m) |
| 2015-06-30 | (m) | $17.55M | $132.07M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $15.19M | $170.26M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $15.66M | $31.01M | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | $14.04M | $29.05M | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | $12.05M | $37.45M | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $10.61M | $105.53M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $11.70M | $44.79M | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | $13.32M | $34.89M | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | $14.57M | $44.31M | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $13.88M | $31.55M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $15.65M | $63.75M | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | $23.11M | $44.49M | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | $29.15M | $42.02M | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | $36.63M | $76.94M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $47.11M | $50.11M | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | $48.44M | $39.52M | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | $49.99M | $18.84M | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | $24.39M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $52.78M | $54.05M | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | $77.33M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $95.12M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $37.33M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $68.47M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |